DataMEDS Acquires Helomics AI Cancer Diagnostics Lab for $1.5M
MEDS sits 97% above its 52-week low of $0.823 on elevated volume (47× avg).
Summary
DataMEDS completed the acquisition of Helomics, an AI cancer diagnostics lab and precision oncology CRO, from Axe Compute for $1.5M in stock and a note, plus $1.5M cash. The deal brings a CLIA/CAP-certified lab, equipment, and the Predictive Oncology CRO business with no third-party debt. This expands DataMEDS into oncology, complementing its existing GLP-1 and Long COVID services. The transaction follows a period of financial strain for DataMEDS, including a $26.1M Q2 loss and going concern doubt, making this asset acquisition a notable strategic move. Axe Compute retains shareholder exposure to Helomics' future.
At the time of this announcement, MEDS was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.82 to $75.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.